Manuscripts
Showing 1557 manuscripts.
HIV-1 Drug Resistance and Second-line Treatment in Children Randomized to Switch at Low versus Higher RNA Thresholds
Citation
Susan Fiscus , Yacine Saidi , Eleni Nastouli , Lynda Harper , Alexandra Compagnucci , Abdel Babiker , Ross McKinney , Diana Gibb , Gareth Tudor-Williams , the PENPACT-1 (PENTA 9/PACTG 390) Study Team, Linda Harrison, Ann Melvin. HIV-1 Drug Resistance and Second-line Treatment in Children Randomized to Switch at Low versus Higher RNA Thresholds. Journal of Acquired Immune Deficiency Syndromes. 2015. 70: 42-53. PMID: 26322666Year
2015
Journal
Journal of Acquired Immune Deficiency Syndromes
Cell-Associated HIV-1 DNA and RNA Decay Dynamics during Early Combination Antiretroviral Therapy in HIV-1-Infected Infants
Citation
Kaitlin Rainwater-Lovett, Carrie Ziemniak, Katherine Luzuriaga, Edmund V. Capparelli, Gayane Yenokyan, Deborah Persaud, Priyanka Uprety, Ellen G. Chadwick. Cell-Associated HIV-1 DNA and RNA Decay Dynamics during Early Combination Antiretroviral Therapy in HIV-1-Infected Infants. Clinical Infectious Diseases. 2015. 15: 1862-70. PMID: 26270687Year
2015
Journal
Clinical Infectious Diseases
Study
P1030
Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.
Citation
T Fenton, CV Fletcher, JJ Kiser, Mofenson LM, E Smith, B Graham, M Mathew, G Aldrovani, PACTG 1020A Study Team, RM Rutsein, P Samson. Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.. Pediatric Infectious Disease Journal. 2015. 34: 162-167. PMID: 25232777Year
2015
Journal
Pediatric Infectious Disease Journal
Study
P1020A
Changing Trends in Complications and Mortality Rates Among US Youth and Young Adults With HIV Infection in the Era of Combination Antiretroviral Therapy
Citation
Miriam Chernoff, Mark J Abzug, Myron J Levin, George R Seage III, James M Oleske, Murli U Purswani, Rohan Hazra, Shirley Traite, Bonnie Zimmer, Russell B Van Dyke, Gayatri Mirani, Paige L Williams, IMPAACT P1074 Study Team. Changing Trends in Complications and Mortality Rates Among US Youth and Young Adults With HIV Infection in the Era of Combination Antiretroviral Therapy. Clinical Infectious Diseases. 2015. 61: 1850-61. PMID: 26270680Year
2015
Journal
Clinical Infectious Diseases
Study
P1074
Screening for Sexually Transmitted Infections in Antenatal Care is Especially Important Among HIV-infected Women
Citation
SH Vermund. Screening for Sexually Transmitted Infections in Antenatal Care is Especially Important Among HIV-infected Women. Sexually Transmitted Diseases. 2015. 42: 566-568. PMID: 26372928Year
2015
Journal
Sexually Transmitted Diseases
Chlamydia and Gonorrhea in HIV-infected Pregnant Women and Adverse Infant Outcomes
Citation
Jiahong Xu, Jorge Pinto, Bonnie Ank, Marisa Mussi-Pinhata, Claire C. Bristow, Mariana Ceriotto, Mariza G Morgado, Daisy Maria Machado, D. Heather Watts, Yvonne J Bryson, Fred Weir, Beatriz Grinsztejn, David Persing, Francisco I Bastos, Lynne M. Mofenson, George Siberry, Valdilea G. Veloso, Karin Neilsen-Saines for the NICHD HPTN 040 Study Team, Jose Henrique Pilotto, Esau Joao, Glenda Gray, Gerhard Theron, Breno Santos, Kristina Adachi, Rosana Fonseca, Jeffrey D Klasner, Regis Kreitchmann. Chlamydia and Gonorrhea in HIV-infected Pregnant Women and Adverse Infant Outcomes. Sexually Transmitted Diseases. 2015. 42: 554-65. PMID: 26372927Year
2015
Journal
Sexually Transmitted Diseases
Changing Trends in Complications and Mortality among US Youth and Young Adults with
HIV Infection in the Era of Combination Antiretroviral Therapy
Citation
Miriam Chernoff, Mark Abzug, Myron Levin, George Seage, James Oleske, Murli Purswani, Rohan Hazra, Shirley Traite, Bonnie Zimmer, Russell Van Dyke for the IMPAACT P1074 team, Gayatri Mirani, Paige Williams. Changing Trends in Complications and Mortality among US Youth and Young Adults with HIV Infection in the Era of Combination Antiretroviral Therapy. Clinical Infectious Diseases. 2015. 61: 1850-1861.Year
2015
Journal
Clinical Infectious Diseases
Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age
Citation
EP Acosta, H Teppler, B Homony, B Graham, T Fenton, X Xu, ML Rizk, SA Spector, LM Frenkel, C Worrell, E Handelsman, A Wiznia, S Nachman, C Alvero. Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age. Journal of Pediatric Infectious Disease Society. 2015. 4: e76-83. PMID: 26582887Year
2015
Journal
Journal of Pediatric Infectious Disease Society
Study
P1066
Population Pharmacokinetic Analysis of Raltegravir Pediatric Formulations in HIV-infected Children 4 weeks to 18 years of age
Citation
C Bennetto-Hood, L Wenning, H Teppler, B Homony, B Graham, C Fry, S Nachman, A Wiznia, C Worrell, B Smith, EP Acosta, ML Rizk, L Du. Population Pharmacokinetic Analysis of Raltegravir Pediatric Formulations in HIV-infected Children 4 weeks to 18 years of age. 2015. PMID: 25753401Year
2015
Study
P1066
Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort study
Citation
Deborah Kacanek, Michael D Hughes, Arlene Bardeguez, Elizabeth Livingston, Alice Stek, David E Shapiro, Ruth Tuomala, Ingrid T Katz, Erin Leister. Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort study. Annals of Internal Medicine. 2015. 162: 90-99. PMID: 25599347Year
2015
Journal
Annals of Internal Medicine